Antiphospholipid antibodies in young myocardial infarction patients

被引:0
作者
Mishra, Mahendra N. [1 ]
Kalra, Ravi [2 ]
Gupta, Mahendra K. [3 ]
机构
[1] Command Hosp SC, Dept Pathol, Pune 411040, Maharashtra, India
[2] INHS Asvini, Dept Cardiol, Bombay 400005, Maharashtra, India
[3] Bombay Hosp & Med Res Ctr, Dept Pathol, Bombay 400013, Maharashtra, India
关键词
myocardial infarction; anticardiolipin antibodies; lupus anticoagulants;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myocardial infarction (MI) is a multi-factorial disease which claims many young lives. There are very few Indian studies that have investigated antiphospholipid antibodies (APLs) in MI patients. APLs have been implicated in arterial thrombosis including premature coronary artery and cerebrovascular thrombosis. In the present study, the prevalence of two clinically significant APLs - anticardiolipin antibody (ACA) and lupus anticoagulants (LA) in young MI patients was studied and compared with age- and sex-matched controls. Fifty healthy blood donors and 40 young MI patients (less than 45 yrs) diagnosed according to the American Heart Association guidelines were recruited for the study. The criteria for diagnosis were presence of atleast two of three classical findings including: clinical symptoms, diagnostic ECG, and presence of one or more cardiac biomarkers out of raised CK-MB isoform and T-troponin on serial measurement. LA and ACA were tested by lupus-sensitive activated partial thromboplastin time (aPTT) and ELISA respectively. Elevation of ACA was observed in 9 patients, while 6 were positive for LA. ACA of IgG isotype was detected in 8 patients. One patient had LA and raised ACA of IgG and IgM isotypes. Antiphospholipid antibodies were found to be significantly associated with MI in young patients, when considered together (p<0.05) and in coronary thrombosis, mild elevation of ACA may be considered significant.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 18 条
[1]   Antiphospholipid thrombosis syndromes [J].
Bick, RL .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2003, 17 (01) :115-+
[2]   Syndromes of thrombosis and hypercoagulability - Congenital and acquired causes of thrombosis [J].
Bick, RL ;
Kaplan, H .
MEDICAL CLINICS OF NORTH AMERICA, 1998, 82 (03) :409-+
[3]   Anticardiolipin antibodies and recurrent coronary events - A prospective study of 1150 patients [J].
Bili, A ;
Moss, AJ ;
Francis, CW ;
Zareba, W ;
Watelet, LFM ;
Sanz, I .
CIRCULATION, 2000, 102 (11) :1258-1263
[4]  
Chandrashekhara S, 2003, J Assoc Physicians India, V51, P359
[5]  
Enas E A, 1997, Indian Heart J, V49, P25
[6]   Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome [J].
Galli, M ;
Luciani, D ;
Bertolini, G ;
Barbui, T .
BLOOD, 2003, 102 (08) :2717-2723
[7]   DETECTION AND IMPORTANCE OF ANTICARDIOLIPIN ANTIBODIES [J].
KHAMASHTA, MA ;
HUGHES, GRV .
JOURNAL OF CLINICAL PATHOLOGY, 1993, 46 (02) :104-107
[8]   IMMUNE MEDIATED MECHANISM FOR THROMBOSIS - ANTIPHOSPHOLIPID ANTIBODY-BINDING TO PLATELET MEMBRANES [J].
KHAMASHTA, MA ;
HARRIS, EN ;
GHARAVI, AE ;
DERUE, G ;
GIL, A ;
VAZQUEZ, JJ ;
HUGHES, GRV .
ANNALS OF THE RHEUMATIC DISEASES, 1988, 47 (10) :849-854
[9]  
Kumar K S D, 2002, J Postgrad Med, V48, P5
[10]   Case definitions for acute coronary heart disease in epidemiology and clinical research studies - A statement from the AHA council on epidemiology and prevention; AHA Statistics Committee; World Heart Federation Council on epidemiology and prevention; the European Society of Cardiology working group on epidemiology and prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute [J].
Luepker, RV ;
Apple, FS ;
Christenson, RH ;
Crow, RS ;
Fortmann, SP ;
Goff, D ;
Goldberg, RJ ;
Hand, MM ;
Jaffe, AS ;
Julian, DG ;
Levy, D ;
Manolio, T ;
Mendis, S ;
Mensah, G ;
Pajak, A ;
Prineas, RJ ;
Reddy, S ;
Roger, VL ;
Rosamond, WD ;
Shahar, E ;
Sharrett, AR ;
Sorlie, P ;
Tunstall-Pedoe, H .
CIRCULATION, 2003, 108 (20) :2543-2549